Private Market View

Harmonic Discovery

New York, NY · Founded 2021 · Privately Held (backing)

PA Mark · $/share
$16
Sep 2026
Implied valuation
Total raised
$8.1M
Last round

Key facts

as of Sep 2026
  • It has raised $8.1M; the latest was Accelerator/Incubator in Sep 2025.
  • Notable investors include Y Combinator, Google for Startups, Caffeinated Capital, Hub71, Johnson & Johnson Innovation - JLABS13 tracked in total.
  • 1 institutional filer reports fund marks on Harmonic Discovery across 1 filings.
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$16per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 1 inputs:N-PORT marks 100%
Free account
See the evidence behind this price
  • ·The complete investor list — 13 names
  • ·Watchlist + deal alerts for Harmonic Discovery
  • ·The full record, as it builds
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Harmonic Discovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

1 filers · latest Jun 2026

1 SEC-registered fund reported 1 fair-value mark on Harmonic Discovery between Jun 2026 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.

Funding rounds

No rounds on record

No funding rounds for Harmonic Discovery are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Harmonic Discovery

Developer of a kinase inhibitor drug platform designed to overcome cancer resistance mechanisms. The company's platform integrates biological screening and medicinal chemistry with computational chemistry, as well as uses structural modeling and machine learning to predict likely clinical resistance mutations and optimize the design of small molecule therapeutics to maintain key targets and avoid harmful off-target interactions, enabling medical practitioners to treat cancer effectively.

Sector
Healthcare
HQ
New York, NY, United States
Founded
2021
Employees
7
Ownership
Privately Held (backing)